Results for

Hemp - Manufacturer Producer - China

Product recommendations

Hemp Tea

Croatia

Hemp

France

Hemp extract drops CBD Isolate based 10 ml

Poland

Provacan

United Kingdom

See more products

HYBIO PHARMACEUTICAL CO. LTD.

China

Founded in 1998, Hybio is a leading peptide pharmaceutical company and the first going public in China (2011, stock code 300199). We offer a full range of peptide products (API & FDF) and services (CRO & CDMO). Hybio Group currently owns 8 subsidiaries and branches, with its Wuhan subsidiary as an API production base, Pingshan branch as a FDF production base, Changee subsidiary as a medical device base, Dali Biotech subsidiary as hemp processing base etc... Hybio Headquarters in Shenzhen has passed local & national NMPA GMP inspection for over 90 times, overseas FDA, EU, ANVISA, KFDA (etc.) GMP inspections for 8 times and customer audits for over 50 times. It owns over 300 invention patents and 102 PCTs, with more than 100 patents authorized. Hybio Wuhan subsidiary is a specialized peptide API manufacturing base, which was put into production in 2019. The full capacity for peptide API can be up to 1000kg/year and the current capacity is around 300kg/year. Main APIs are Liraglutide, Semaglutide, Tirzepatide, Glatiramer, Ganirelix, Cetrorelix, Degarelix, Atosiban, Oxytocin, Carbetocin, Terlipressin, Desmopressin, Linaclotide, Plecanatide, Leuprorelin, Triptorelin, Teriparatide, Eptifibatide, Octreotide, Lanreotide, Somatostatin, etc.

See all products

Filters

Results for

Hemp - Manufacturer Producer - China

Number of results

1 Company